neurology
Multiple sclerosis

B-cell depleting therapies such as rituximab have become ‘therapeutic pariahs’ in COVID era

B-cell depleting therapies such as rituximab have become ‘therapeutic pariahs’ during the pandemic because of their associations with poor COVID outcomes, Australian clinicians say. Two recent studies have found that B-cell depleting therapies stand out as the only immunosuppressive drugs that appear to increase the risk of adverse outcomes in patients with COVID-19 disease. One ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic